



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thomas D. Madden et al.
Application No. : 10/788,649
Filed : February 27, 2004
For : LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF

Examiner : Gollamudi S. Kishore
Art Unit : 1615
Docket No. : 480208.408D1
Date : October 11, 2005

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:


In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. A copy of the cited U.S. patent is not required and accordingly has not been provided. Copies of the other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC




Carol D. Laherty Ph.D.
Registration No. 51,909

Enclosures:

Postcard
Information Disclosure Statement
Cited References (2)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

699717



EXPRESS MAIL NO. EV530945453US

Sheet 1 of 1U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

480208.408D1

APPLICATION NO.

10/788,649

APPLICANTS

Thomas D. Madden et al.

FILING DATE

February 27, 2004

GROUP ART UNIT

1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,543,152	08/06/96	Webb et al.	424	450	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Allen, T., et al., "Subcutaneous Administration of Liposomes: A Comparison with the Intravenous and Intraperitoneal Routes of Injection," <i>Biochim Biophys Acta</i> . 1150(1):9-16, July 25, 1993.
	AQ	Boman, N., et al., "Vincristine-induced Dermal Toxicity is Significantly Reduced When the Drug is Given in Liposomes," <i>Cancer Chemother Pharmacol.</i> , 37(4):351-5, 1996.
	AR	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).